ハンチントン病治療市場の2028年までの予測-治療法（疾患修飾療法、対症療法）、薬剤、エンドユーザー、地域別の世界分析

Stratistics MRCによると、ハンチントン病治療の世界市場は、2022年に85億米ドルを占め、2028年には187億米ドルに達すると予測され、予測期間中に14.1%のCAGRで成長するとされています。

ハンチントン病は、脳の神経細胞の破壊が進行し、主に身体運動、感情、認知能力に影響を及ぼす稀な遺伝性疾患です。脳の神経細胞が誤作動を起こし、神経原線維のもつれと呼ばれるタンパク質の塊を作り、運動、思考、推論、気分などに影響を与える疾患です。制御不能な動きや筋肉の痙攣（コレア）、言語パターンの変化、うつ病、不安、性格の変化などを引き起こすことがあります。

米国ハンチントン病協会（HDSA）によると、2021年の症状のある米国人は約41,000人で、この病気を遺伝するリスクのある人は200,000人を超えるとされています。

市場力学

ドライバーです：

ハンチントン病の発症率の上昇

世界のハンチントン病の罹患率の上昇は、市場成長を促進する主要な要因の一つです。この処置は、制御不能なピクピクと身動きの取れない動きを止めるために頻繁に使用され、生活の質を向上させます。さらに、臨床試験、強力な薬剤タイプのパイプライン、改善された医療処置や治療法の採用の増加が、市場の成長を促進すると予想されます。

抑制要因

承認された薬剤の不足と厳しい規制政策

現在、本疾患に関連するコレアの治療薬として承認されているのは2種類のみで、これらの薬剤は症状の管理・抑制にとどまり、病気を治すことはできません。世界中の企業が医薬品を承認するためには、厳しい規制のハードルをクリアする必要があります。このような規制の制限は市場参入企業の嗜好に影響を与える可能性があり、その結果、予測期間中の市場成長は鈍化することになります。

機会

研究開発の活発化

ハンチントン病の治療アプローチについては、有効な治療法や薬剤がないため、膨大な研究開発領域があります。このことは、予測期間中の市場成長を大きく後押しすると予想されます。さらに、新薬の開発を促進する政府の有望な取り組みも、市場の成長を支える要因のひとつになると推測されます。

脅威

薬剤の入手が困難なこと

厳しい政策や規制のため、認可された医薬品の数は限られています。世界の多くの地域でこの病気に関する知識が不足しているため、市場の拡大が制約されることが予想されます。多くの医薬品が有効性を示せなかったり、重大な毒性との関連性が指摘されており、この病気を治療するための医薬品の発見には大きな課題がありました。これが市場成長の妨げになると予想されます。

COVID-19の影響

COVID-19の発生は、ハンチントン病治療の市場規模に悪影響を及ぼすと予測されます。COVID-19の患者を増やすために、世界中のかなりの数の診療所や病院がリストラを行っています。患者さんが急増したため、重要でない業務が滞ることもありました。ヘルスケアに必要な物資の生産・配送が封鎖された結果、ストップしました。ヘルスケアへのアクセス不足、医療現場での人員不足、COVID-19に関連した入院患者の増加なども、市場に影響を与える変数として追加されています。

予測期間中、疾患修飾療法分野が最も大きくなると予想される

疾患修飾療法分野は、疾患修飾療法の研究開発の増加により、有利な成長を遂げると推定されます。疾患修飾療法は、静脈内または経口で投与することにより、現在の症状を軽減したり、進行を遅らせたりすることができます。疾患修飾療法は、この疾患に関連する精神疾患やうつ病などの問題を改善することができますが、患者の死亡率に変化をもたらすことは確認されていません。

抗うつ薬セグメントは予測期間中に最も高いCAGRが予想される

抗うつ剤は、精神的な安定を取り戻すことを目的としているため、予測期間中に最も速いCAGRの成長が見込まれます。抗うつ剤は、臨床的なうつ病、難聴、社会不安、不安、その他の症状を改善する処方薬です。抗うつ剤による治療は、主に重度のうつ病の症状を軽減することに重点を置いています。これらが、この分野の成長を牽引しています。

最もシェアの高い地域

アジア太平洋地域は、この疾患の有病率が比較的低いことから、予測期間中に最大の市場シェアを占めると予測されます。しかし、これらの地域では、予測期間中に償還政策が改善されるとともに、利用可能な治療法に対する患者の意識が高まっていることが、成長見通しに寄与すると考えられます。

CAGRが最も高い地域：

北米は、製品の普及が進んでいることから、予測期間中に最も高いCAGRを示すと予測されます。この疾患に関する一般市民の意識が高く、研究資金を通じて多くの公的機関や民間団体から支援を受け、この疾患の研究が促進されています。各国政府が国民の健康状態を改善するための取り組みを強化していることから、同地域の市場は成長すると予想されます。

市場の主なプレイヤー

ハンチントン病治療市場でプロファイルされている主要企業には、Novartis AG、Teva Pharmaceutical Industries Ltd.、Dr. Reddy's Laboratories Ltd.、Sun Pharmaceutical Industries, Inc.、ルパン、ヘテロ、Hikma Pharmaceuticals PLC, Bausch Health Companies Inc.があります、Alterity Therapeutics、H. Lundbeck A/S、Neurocrine Biosciences, Inc.、Annexon Biosciences、PTC Therapeutics、Prilenia Therapeutics、Amneal Pharmaceuticals LLC.、SOM BIOTECH、Vertex Pharmaceuticals Incorporatedです。

主な発展：

2021年12月、ノバルティスAGは、ハンチントン病治療薬としてBranaplamのファストトラック指定をFDAから受けた。Branaplamは、ハンチントン病につながる神経細胞の変性を引き起こす原因となるHTTタンパク質を標的とするmRNAスプライシングモジュレーターです。

2021年10月、テバ・ファーマシューティカル・インダストリーズ・リミテッドがハンチントン病治療に伴うコレアの治療薬として、またブラジルにおける遅発性ジスキネジアの治療薬として販売承認を取得しました。

当レポートが提供するもの

• 地域レベルおよび国レベル区分の市場シェア評価
• 新規参入企業への戦略的提言
• 2020年、2021年、2022年、2025年、2028年の市場データを網羅
• 市場促進要因（市場動向、制約要因、機会、脅威、課題、投資機会・推奨事項など）
• 市場推定に基づく主要なビジネスセグメントにおける戦略的な提言
• 競合情勢とその動向
• 詳細な戦略、財務、最近の動向を含む企業プロファイル
• サプライチェーンの動向は、最新の技術進歩をマッピングしています。

無料カスタマイズの提供

本レポートをご購入いただいたお客様には、以下のいずれかの無料カスタマイズをご提供いたします。

• 企業プロファイル
  • 追加市場プレイヤーの包括的なプロファイリング（最大3名まで）
  • 主要プレイヤーのSWOT分析（3名まで）
• 地域別セグメント
  • お客様のご希望により、主要国の市場推計・予測・CAGRを提供（注：フィージビリティチェック別）
• 競合ベンチマーキング
  • 製品ポートフォリオ、地理的プレゼンス、戦略的提携に基づく主要プレイヤーのベンチマーキング

目次

第1章 エグゼクティブサマリー

第2章 序文

• 概要
• ステークホルダー
• 調査範囲
• 調査手法
  • データマイニング
  • データ分析
  • データ検証
  • 調査アプローチ
• 調査情報源
  • 1次調査情報源
  • 2次調査情報源
  • 仮定

第3章 市場動向分析

• 促進要因
• 抑制要因
• 機会
• 脅威
• エンドユーザー分析
• 新興市場
• COVID-19の影響

第4章 ポーターズファイブフォース分析

• 供給企業の交渉力
• 買い手の交渉力
• 代替品の脅威
• 新規参入業者の脅威
• 競争企業間の敵対関係

第5章 世界のハンチントン病治療市場：治療別

• 疾患修飾療法
• 対症療法

第6章 世界のハンチントン病治療市場：薬剤別

• 抗うつ薬
• 抗精神病薬
• 精神安定剤
• テトラベナジン
• その他の薬

第7章 世界のハンチントン病治療市場：エンドユーザー別

• 診療所
• 病院
• 小売薬局
• オンライン薬局
• その他のエンドユーザー

第8章 世界のハンチントン病治療市場：地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • イタリア
  • フランス
  • スペイン
  • その他欧州
• アジア太平洋地域
  • 日本
  • 中国
  • インド
  • オーストラリア
  • ニュージーランド
  • 韓国
  • その他アジア太平洋地域
• 南米
  • アルゼンチン
  • ブラジル
  • チリ
  • その他南米
• 中東とアフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • カタール
  • 南アフリカ
  • その他中東

第9章 主な発展

• 契約、パートナーシップ、コラボレーション、合弁事業
• 買収と合併
• 新製品の発売
• 事業拡大
• その他の主要戦略

第10章 企業プロファイル

• Novartis AG
• Teva Pharmaceutical Industries Ltd.
• Dr. Reddy's Laboratories Ltd.
• Sun Pharmaceutical Industries, Inc.
• Lupin
• Hetero
• Hikma Pharmaceuticals PLC
• Bausch Health Companies Inc.
• Alterity Therapeutics
• H. Lundbeck A/S
• Neurocrine Biosciences, Inc.
• Annexon Biosciences
• PTC Therapeutics
• Prilenia Therapeutics
• Amneal Pharmaceuticals LLC.
• SOM BIOTECH
• Vertex Pharmaceuticals Incorporated

List of Tables

• Table 1 Global Huntington's Disease Treatment Market Outlook, By Region (2020-2028) ($MN)
• Table 2 Global Huntington's Disease Treatment Market Outlook, By Treatment (2020-2028) ($MN)
• Table 3 Global Huntington's Disease Treatment Market Outlook, By Disease-modifying therapies (2020-2028) ($MN)
• Table 4 Global Huntington's Disease Treatment Market Outlook, By Symptomatic treatment (2020-2028) ($MN)
• Table 5 Global Huntington's Disease Treatment Market Outlook, By Drug (2020-2028) ($MN)
• Table 6 Global Huntington's Disease Treatment Market Outlook, By Antidepressants (2020-2028) ($MN)
• Table 7 Global Huntington's Disease Treatment Market Outlook, By Antipsychotic Drugs (2020-2028) ($MN)
• Table 8 Global Huntington's Disease Treatment Market Outlook, By Tranquilizers (2020-2028) ($MN)
• Table 9 Global Huntington's Disease Treatment Market Outlook, By Tetrabenazine (2020-2028) ($MN)
• Table 10 Global Huntington's Disease Treatment Market Outlook, By Other Drugs (2020-2028) ($MN)
• Table 11 Global Huntington's Disease Treatment Market Outlook, By End User (2020-2028) ($MN)
• Table 12 Global Huntington's Disease Treatment Market Outlook, By Clinics (2020-2028) ($MN)
• Table 13 Global Huntington's Disease Treatment Market Outlook, By Hospital (2020-2028) ($MN)
• Table 14 Global Huntington's Disease Treatment Market Outlook, By Retail Pharmacies (2020-2028) ($MN)
• Table 15 Global Huntington's Disease Treatment Market Outlook, By Online Pharmacies (2020-2028) ($MN)
• Table 16 Global Huntington's Disease Treatment Market Outlook, By Other End Users (2020-2028) ($MN)
• Table 17 North America Huntington's Disease Treatment Market Outlook, By Country (2020-2028) ($MN)
• Table 18 North America Huntington's Disease Treatment Market Outlook, By Treatment (2020-2028) ($MN)
• Table 19 North America Huntington's Disease Treatment Market Outlook, By Disease-modifying therapies (2020-2028) ($MN)
• Table 20 North America Huntington's Disease Treatment Market Outlook, By Symptomatic treatment (2020-2028) ($MN)
• Table 21 North America Huntington's Disease Treatment Market Outlook, By Drug (2020-2028) ($MN)
• Table 22 North America Huntington's Disease Treatment Market Outlook, By Antidepressants (2020-2028) ($MN)
• Table 23 North America Huntington's Disease Treatment Market Outlook, By Antipsychotic Drugs (2020-2028) ($MN)
• Table 24 North America Huntington's Disease Treatment Market Outlook, By Tranquilizers (2020-2028) ($MN)
• Table 25 North America Huntington's Disease Treatment Market Outlook, By Tetrabenazine (2020-2028) ($MN)
• Table 26 North America Huntington's Disease Treatment Market Outlook, By Other Drugs (2020-2028) ($MN)
• Table 27 North America Huntington's Disease Treatment Market Outlook, By End User (2020-2028) ($MN)
• Table 28 North America Huntington's Disease Treatment Market Outlook, By Clinics (2020-2028) ($MN)
• Table 29 North America Huntington's Disease Treatment Market Outlook, By Hospital (2020-2028) ($MN)
• Table 30 North America Huntington's Disease Treatment Market Outlook, By Retail Pharmacies (2020-2028) ($MN)
• Table 31 North America Huntington's Disease Treatment Market Outlook, By Online Pharmacies (2020-2028) ($MN)
• Table 32 North America Huntington's Disease Treatment Market Outlook, By Other End Users (2020-2028) ($MN)
• Table 33 Europe Huntington's Disease Treatment Market Outlook, By Country (2020-2028) ($MN)
• Table 34 Europe Huntington's Disease Treatment Market Outlook, By Treatment (2020-2028) ($MN)
• Table 35 Europe Huntington's Disease Treatment Market Outlook, By Disease-modifying therapies (2020-2028) ($MN)
• Table 36 Europe Huntington's Disease Treatment Market Outlook, By Symptomatic treatment (2020-2028) ($MN)
• Table 37 Europe Huntington's Disease Treatment Market Outlook, By Drug (2020-2028) ($MN)
• Table 38 Europe Huntington's Disease Treatment Market Outlook, By Antidepressants (2020-2028) ($MN)
• Table 39 Europe Huntington's Disease Treatment Market Outlook, By Antipsychotic Drugs (2020-2028) ($MN)
• Table 40 Europe Huntington's Disease Treatment Market Outlook, By Tranquilizers (2020-2028) ($MN)
• Table 41 Europe Huntington's Disease Treatment Market Outlook, By Tetrabenazine (2020-2028) ($MN)
• Table 42 Europe Huntington's Disease Treatment Market Outlook, By Other Drugs (2020-2028) ($MN)
• Table 43 Europe Huntington's Disease Treatment Market Outlook, By End User (2020-2028) ($MN)
• Table 44 Europe Huntington's Disease Treatment Market Outlook, By Clinics (2020-2028) ($MN)
• Table 45 Europe Huntington's Disease Treatment Market Outlook, By Hospital (2020-2028) ($MN)
• Table 46 Europe Huntington's Disease Treatment Market Outlook, By Retail Pharmacies (2020-2028) ($MN)
• Table 47 Europe Huntington's Disease Treatment Market Outlook, By Online Pharmacies (2020-2028) ($MN)
• Table 48 Europe Huntington's Disease Treatment Market Outlook, By Other End Users (2020-2028) ($MN)
• Table 49 Asia Pacifiic Huntington's Disease Treatment Market Outlook, By Country (2020-2028) ($MN)
• Table 50 Asia Pacifiic Huntington's Disease Treatment Market Outlook, By Treatment (2020-2028) ($MN)
• Table 51 Asia Pacifiic Huntington's Disease Treatment Market Outlook, By Disease-modifying therapies (2020-2028) ($MN)
• Table 52 Asia Pacifiic Huntington's Disease Treatment Market Outlook, By Symptomatic treatment (2020-2028) ($MN)
• Table 53 Asia Pacifiic Huntington's Disease Treatment Market Outlook, By Drug (2020-2028) ($MN)
• Table 54 Asia Pacifiic Huntington's Disease Treatment Market Outlook, By Antidepressants (2020-2028) ($MN)
• Table 55 Asia Pacifiic Huntington's Disease Treatment Market Outlook, By Antipsychotic Drugs (2020-2028) ($MN)
• Table 56 Asia Pacifiic Huntington's Disease Treatment Market Outlook, By Tranquilizers (2020-2028) ($MN)
• Table 57 Asia Pacifiic Huntington's Disease Treatment Market Outlook, By Tetrabenazine (2020-2028) ($MN)
• Table 58 Asia Pacifiic Huntington's Disease Treatment Market Outlook, By Other Drugs (2020-2028) ($MN)
• Table 59 Asia Pacifiic Huntington's Disease Treatment Market Outlook, By End User (2020-2028) ($MN)
• Table 60 Asia Pacifiic Huntington's Disease Treatment Market Outlook, By Clinics (2020-2028) ($MN)
• Table 61 Asia Pacifiic Huntington's Disease Treatment Market Outlook, By Hospital (2020-2028) ($MN)
• Table 62 Asia Pacifiic Huntington's Disease Treatment Market Outlook, By Retail Pharmacies (2020-2028) ($MN)
• Table 63 Asia Pacifiic Huntington's Disease Treatment Market Outlook, By Online Pharmacies (2020-2028) ($MN)
• Table 64 Asia Pacifiic Huntington's Disease Treatment Market Outlook, By Other End Users (2020-2028) ($MN)
• Table 65 South America Huntington's Disease Treatment Market Outlook, By Country (2020-2028) ($MN)
• Table 66 South America Huntington's Disease Treatment Market Outlook, By Treatment (2020-2028) ($MN)
• Table 67 South America Huntington's Disease Treatment Market Outlook, By Disease-modifying therapies (2020-2028) ($MN)
• Table 68 South America Huntington's Disease Treatment Market Outlook, By Symptomatic treatment (2020-2028) ($MN)
• Table 69 South America Huntington's Disease Treatment Market Outlook, By Drug (2020-2028) ($MN)
• Table 70 South America Huntington's Disease Treatment Market Outlook, By Antidepressants (2020-2028) ($MN)
• Table 71 South America Huntington's Disease Treatment Market Outlook, By Antipsychotic Drugs (2020-2028) ($MN)
• Table 72 South America Huntington's Disease Treatment Market Outlook, By Tranquilizers (2020-2028) ($MN)
• Table 73 South America Huntington's Disease Treatment Market Outlook, By Tetrabenazine (2020-2028) ($MN)
• Table 74 South America Huntington's Disease Treatment Market Outlook, By Other Drugs (2020-2028) ($MN)
• Table 75 South America Huntington's Disease Treatment Market Outlook, By End User (2020-2028) ($MN)
• Table 76 South America Huntington's Disease Treatment Market Outlook, By Clinics (2020-2028) ($MN)
• Table 77 South America Huntington's Disease Treatment Market Outlook, By Hospital (2020-2028) ($MN)
• Table 78 South America Huntington's Disease Treatment Market Outlook, By Retail Pharmacies (2020-2028) ($MN)
• Table 79 South America Huntington's Disease Treatment Market Outlook, By Online Pharmacies (2020-2028) ($MN)
• Table 80 South America Huntington's Disease Treatment Market Outlook, By Other End Users (2020-2028) ($MN)
• Table 81 Middle East & Africa Huntington's Disease Treatment Market Outlook, By Country (2020-2028) ($MN)
• Table 82 Middle East & Africa Huntington's Disease Treatment Market Outlook, By Treatment (2020-2028) ($MN)
• Table 83 Middle East & Africa Huntington's Disease Treatment Market Outlook, By Disease-modifying therapies (2020-2028) ($MN)
• Table 84 Middle East & Africa Huntington's Disease Treatment Market Outlook, By Symptomatic treatment (2020-2028) ($MN)
• Table 85 Middle East & Africa Huntington's Disease Treatment Market Outlook, By Drug (2020-2028) ($MN)
• Table 86 Middle East & Africa Huntington's Disease Treatment Market Outlook, By Antidepressants (2020-2028) ($MN)
• Table 87 Middle East & Africa Huntington's Disease Treatment Market Outlook, By Antipsychotic Drugs (2020-2028) ($MN)
• Table 88 Middle East & Africa Huntington's Disease Treatment Market Outlook, By Tranquilizers (2020-2028) ($MN)
• Table 89 Middle East & Africa Huntington's Disease Treatment Market Outlook, By Tetrabenazine (2020-2028) ($MN)
• Table 90 Middle East & Africa Huntington's Disease Treatment Market Outlook, By Other Drugs (2020-2028) ($MN)
• Table 91 Middle East & Africa Huntington's Disease Treatment Market Outlook, By End User (2020-2028) ($MN)
• Table 92 Middle East & Africa Huntington's Disease Treatment Market Outlook, By Clinics (2020-2028) ($MN)
• Table 93 Middle East & Africa Huntington's Disease Treatment Market Outlook, By Hospital (2020-2028) ($MN)
• Table 94 Middle East & Africa Huntington's Disease Treatment Market Outlook, By Retail Pharmacies (2020-2028) ($MN)
• Table 95 Middle East & Africa Huntington's Disease Treatment Market Outlook, By Online Pharmacies (2020-2028) ($MN)
• Table 96 Middle East & Africa Huntington's Disease Treatment Market Outlook, By Other End Users (2020-2028) ($MN)

According to Stratistics MRC, the Global Huntington's Disease Treatment Market is accounted for $8.5 billion in 2022 and is expected to reach $18.7 billion by 2028 growing at a CAGR of 14.1% during the forecast period. Huntington's disease is a rare inherited disease that causes progressive breakdown of nerve cells in the brain, mainly affecting physical movements, emotions and cognitive abilities. It is a condition in which the nerve cells of the brain malfunction and create clumps of a protein called neurofibrillary tangles that affect movement, thinking, reasoning, moods, and more. It can cause uncontrolled movements or muscle twitches (chorea), changes in speech patterns, depression, anxiety, and personality changes.

According to the Huntington's disease Society of America (HDSA), there were approximately 41,000 symptomatic Americans in 2021, with over 200,000 individuals at risk of inheriting the disease.

Market Dynamics:

Driver:

The rising incidence of Huntington's disease

The rising incidence of Huntington's disease across the globe is one of the primary factors driving the market growth. The procedure is frequently used to stop uncontrollable jerking and writhing motion, which enhances quality of life. In addition, clinical trials, strong drug type pipeline and growing adoption of improved medical treatments and therapies are expected to fuel the market growth.

Restraint:

Lack of approved drugs and stringent regulatory policies

Currently, there are only two drugs approved for the treatment of chorea associated with this condition and these drugs can only manage or control the symptoms but cannot cure the disease. Companies across the globe need to clear strict regulatory hurdles for the approval of drugs. Such regulatory limits may impact market participants' preferences, resulting in slower market growth during the projection period.

Opportunity:

Growing research and development activities

There is a vast area of research and development for Huntington's disease treatment approaches because there is no effective treatment or medication. This is expected to significantly boost market growth during the forecast period. Moreover, the promising government initiatives that promote the development of new drugs are estimated to be another factor supporting the market growth.

Threat:

Limited availability of drugs

The number of licensed pharmaceuticals is limited due to tight policies and restrictions. It is anticipated that the market's expansion will be constrained by the lack of knowledge about this illness in many regions of the world. Many medications have failed to show efficacy or have been linked to significant toxicity, which has presented significant challenges for the discovery of drugs to treat the disease. This is expected to hamper the market growth.

Covid-19 Impact

The COVID-19 outbreak is projected to have a detrimental effect on the size of the market for treating Huntington's disease. To accommodate more patients with COVID-19, a sizable number of clinics and hospitals around the world underwent restructuring. Because of the sharp increase in patients, non-essential operations could be delayed. Production and delivery of supplies for healthcare were halted as a result of the lockdown. Lack of access to healthcare, a staffing deficit in the medical field, and an increase in COVID-19-related hospitalisation are some additional variables that have an impact on the market.

The disease-modifying therapies segment is expected to be the largest during the forecast period

The disease-modifying therapies segment is estimated to have a lucrative growth, due to an increase in disease-modifying therapy R&D. They can be administered intravenously or orally to lessen current symptoms or slow their progression. Disease-modifying therapies can help with problems like psychological illnesses and depression linked to this condition, but they have not been found to change patient mortality rates.

The antidepressants segment is expected to have the highest CAGR during the forecast period

The antidepressants segment is anticipated to witness the fastest CAGR growth during the forecast period, due to they are intended to restore the mental stability. Antidepressants are prescription medications that can help with symptoms of clinical depression, dysthymia, social anxiety, anxiety, and other conditions. Treatment with antidepressants focuses primarily on reducing the symptoms of severe depression. These are driving the segment growth.

Region with Largest share:

Asia Pacific is projected to hold the largest market share during the forecast period owing to the comparatively lower prevalence rate of this condition amongst the population. However, increasing awareness among the patient population toward available treatment along with improving reimbursement policies in these regions during the forecast period will contribute to their growth prospects.

Region with highest CAGR:

North America is projected to have the highest CAGR over the forecast period, owing to the increasing product penetration. A high level of public awareness about the condition, as well as growing support from numerous public and private organisations through research funding, to expedite the study of this disease. As governments take more initiatives to improve the health status of the populations, the market in the region is expected to grow.

Key Players in the market

Some of the key players profiled in the Huntington's Disease Treatment Market include Novartis AG, Teva Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., Sun Pharmaceutical Industries, Inc., Lupin, Hetero, Hikma Pharmaceuticals PLC, Bausch Health Companies Inc., Alterity Therapeutics, H. Lundbeck A/S, Neurocrine Biosciences, Inc., Annexon Biosciences, PTC Therapeutics, Prilenia Therapeutics, Amneal Pharmaceuticals LLC., SOM BIOTECH and Vertex Pharmaceuticals Incorporated.

Key Developments:

In December 2021, Novartis AG received Fast Track designation for Branaplam from the FDA for Huntington's disease treatment. Branaplam is an mRNA splicing modulator that targets the HTT protein responsible for causing the degeneration of nerve cells leading to Huntington's disease.

In October 2021, Teva Pharmaceutical Industries Ltd. Received marketing approval for the treatment of chorea associated with Huntington's disease treatment and for the treatment of tardive dyskinesia in Brazil.

Treatments Covered:

• Disease-modifying therapies
• Symptomatic treatment

Drugs Covered:

• Antidepressants
• Antipsychotic Drugs
• Tranquilizers
• Tetrabenazine
• Other Drugs

End Users Covered:

• Clinics
• Hospital
• Retail Pharmacies
• Online Pharmacies
• Other End Users

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2020, 2021, 2022, 2025, and 2028
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 End User Analysis
• 3.7 Emerging Markets
• 3.8 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Huntington's Disease Treatment Market, By Treatment

• 5.1 Introduction
• 5.2 Disease-modifying therapies
• 5.3 Symptomatic treatment

6 Global Huntington's Disease Treatment Market, By Drug

• 6.1 Introduction
• 6.2 Antidepressants
• 6.3 Antipsychotic Drugs
• 6.4 Tranquilizers
• 6.5 Tetrabenazine
• 6.6 Other Drugs

7 Global Huntington's Disease Treatment Market, By End User

• 7.1 Introduction
• 7.2 Clinics
• 7.3 Hospital
• 7.4 Retail Pharmacies
• 7.5 Online Pharmacies
• 7.6 Other End Users

8 Global Huntington's Disease Treatment Market, By Geography

• 8.1 Introduction
• 8.2 North America
  • 8.2.1 US
  • 8.2.2 Canada
  • 8.2.3 Mexico
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 Italy
  • 8.3.4 France
  • 8.3.5 Spain
  • 8.3.6 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 Japan
  • 8.4.2 China
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 New Zealand
  • 8.4.6 South Korea
  • 8.4.7 Rest of Asia Pacific
• 8.5 South America
  • 8.5.1 Argentina
  • 8.5.2 Brazil
  • 8.5.3 Chile
  • 8.5.4 Rest of South America
• 8.6 Middle East & Africa
  • 8.6.1 Saudi Arabia
  • 8.6.2 UAE
  • 8.6.3 Qatar
  • 8.6.4 South Africa
  • 8.6.5 Rest of Middle East & Africa

9 Key Developments

• 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 9.2 Acquisitions & Mergers
• 9.3 New Product Launch
• 9.4 Expansions
• 9.5 Other Key Strategies

10 Company Profiling

• 10.1 Novartis AG
• 10.2 Teva Pharmaceutical Industries Ltd.
• 10.3 Dr. Reddy's Laboratories Ltd.
• 10.4 Sun Pharmaceutical Industries, Inc.
• 10.5 Lupin
• 10.6 Hetero
• 10.7 Hikma Pharmaceuticals PLC
• 10.8 Bausch Health Companies Inc.
• 10.9 Alterity Therapeutics
• 10.10 H. Lundbeck A/S
• 10.11 Neurocrine Biosciences, Inc.
• 10.12 Annexon Biosciences
• 10.13 PTC Therapeutics
• 10.14 Prilenia Therapeutics
• 10.15 Amneal Pharmaceuticals LLC.
• 10.16 SOM BIOTECH
• 10.17 Vertex Pharmaceuticals Incorporated